Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian Cancer

Video

Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.

Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.

Recently, PARP inhibitors have caused the biggest shift in the landscape of ovarian cancer, according to Berek. PARP inhibitors have shown promise as maintenance therapy, and for those who have tumors that respond to platinum-based chemotherapy. Some of the most impressive data was from the SOLO-1 trial, which showed a significant improvement in progression-free survival with olaparib (Lynparza) as frontline maintenance therapy for patients with BRCA-positive advanced ovarian cancer.

Any high-grade serous tumors, even ones that are not associated with BRCA1/2 mutations, have responded to PARP inhibitors, which Berek says is a major advance. PARP inhibitors are also oral, making them convenient for the patients, and well tolerated. It is a great improvement in quality of life, Berek says. The goal is to create more customized targeted therapies so that people can live longer, fuller lives.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,